In a retrospective analysis of 87 newly diagnosed patients with FLT3-mutated AML treated with either triplet (HMA + Venetoclax + FLT3i) or doublet (HMA + FLT3i) therapy, patients receiving triplet therapy had significantly longer OS without increased cytopenias [72]. Here, FLT3 is linked to acute myeloid leukemia.